Advanced Search
Current and Breaking News for Professionals, Consumers and Media

Click here to learn how to advertise on this site and for ad rates.

Stem Cell Issues Author: Derma Sciences, Inc. Last Updated: Nov 13, 2009 - 7:30:06 PM



To Heal Diabetic Foot Ulcers, A New Drug Harnesses Stem Cells Inside Us All

By Derma Sciences, Inc.
Nov 13, 2009 - 7:26:50 PM



Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust


Email this article
 Printer friendly page
(HealthNewsDigest.com) - Princeton, NJ -- Diabetic foot ulcers are the primary cause of hospital admissions for diabetics. Foot ulcers that heal improperly are at risk for infection, which can lead to amputation. According to the American Diabetes Association, one in four patients with diabetic foot ulcers will eventually require lower-limb amputation. Now science has found a way of mobilizing stem cells within the body to treat this health issue, which affects more than three million Americans annually.

Mesenchymal stem cells (MSCs), as distinct from the embryonic type, may be the key to healing diabetic foot ulcers. These stem cells can differentiate into various cell types. As a fetus develops, MSCs help drive its rapid initial growth; by the time we reach our teens, however, MSCs are mostly found in bone marrow.

When wounded or burned, our skin craves MSCs, which it harbored when first growing. In fact, recent studies show that surgically moving these cells from bone marrow onto hard-to-heal wounds accelerates healing.

In contrast to surgically removing MSCs from bone marrow—a painful, time consuming and expensive process—a new topical drug, the novel angiotensin analog DSC127, appears to activate the mesenchymal stem cells in a patient’s body.

“It appears that DSC127 directs MSCs to the injury site, mobilizing them to help repair wounded or burned skin, accelerate healing and reduce scar formation,” said Edward J. Quilty, Chairman & CEO of Derma Sciences Inc. Based in Princeton, New Jersey, Derma Sciences develops, manufactures, and markets innovative wound care products. “DSC127,” Quilty observed, “thus works as a catalyst for a stem cell treatment that is free of both the ethical controversies surrounding the medical use of fertilized embryos as well as potentially painful surgical interventions.”

Currently in a 75-patient Phase II diabetic foot ulcer clinical trial being conducted at some of the nation’s top institutions, the drug is being considered for additional indications including venous leg ulcers, arterial ulcers, pressure ulcers, thermal and chemical wounds, and scar prevention. Pre-clinical animal studies have demonstrated the efficacy of the compound in accelerating healing and reducing scar formation.

If DSC127 is approved for market, patients with diabetic foot ulcers may find a solution already exists within their own bodies. For more information, visit www.dermasciences.com.

Subscribe to our FREE Ezine and be eligible for Health News, discounted products/services and coupons related to your Health. We publish 24/7.
HealthNewsDigest.com
We videotape Press Conferences, produce SMT's, VNR's, B-rolls, PSA's, - all with distribution: HealthyTelevisionProductions

Top of Page

HealthNewsDigest.com

Stem Cell Issues
Latest Headlines


+ Making Old Stem Cells Act Young Again
+ Umbilical Cord Could Be New Source of Plentiful Stem Cells
+ Regents Uphold Current Embryonic Stem Cell Research Policy
+ To Heal Diabetic Foot Ulcers, A New Drug Harnesses Stem Cells Inside Us All
+ MU Scientists Convert Pigs' Connective Tissue Cells into Stem Cells



Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions